European Physician Survey of EGFR Inhibitor Prescribing Patterns
Survey of Oncologists in Europe to Evaluate Their Knowledge of KRAS Testing
1 other identifier
observational
453
0 countries
N/A
Brief Summary
To ensure the appropriate administration of Vectibix for the treatment of mCRC with wild-type KRAS in real-world practice, it is important to understand the awareness of practicing oncologists regarding the correct indication and appropriate administration of Vectibix. It is also critical to monitor changes in oncologists' awareness and practice between the different rounds of the study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2012
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2012
CompletedFirst Submitted
Initial submission to the registry
June 5, 2012
CompletedFirst Posted
Study publicly available on registry
July 30, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2014
CompletedSeptember 9, 2022
September 1, 2022
2.7 years
June 5, 2012
September 8, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Proportion of oncologists who are aware of the correct indication of Vectibix, with regard to tumor KRAS status and who conduct a KRAS test prior to initiation of Vectibix treatment
Trend survey of physicians performed over 3 years
Proportion of oncologists who conduct a KRAS test prior to the initiation of Vectibix treatment
Trend survey of physicians performed over 3 years
Proportion of oncologists who administer Vectibix in mCRC patients with mutant KRAS tumors or with KRAS status unknown
Trend survey of physicians performed over 3 years
Proportion of oncologists who administer Vectibix simultaneously with oxaliplatin-containing chemotherapy in mCRC patients with mutant KRAS tumors or patients with tumor KRAS status unknown
Trend survey of physicians performed over 3 years
Study Arms (3)
Round 1
survey of 150 oncologists
Round 2
survey of 150 oncologists approximately 12 months after round 1
Round 3
survey of 150 oncologists approximately 24 months after round 1
Interventions
Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months
Eligibility Criteria
Physician's satisfying all of the eligibility criteria are eligible to be enrolled in the survey
You may qualify if:
- Must be a practicing oncology specialist
- Must treat at least 3 new or continuing patients with metastatic colorectal cancer in the last quarter
- Must have prescribed Vectibix within the last 6 months to metastatic colorectal cancer patients
You may not qualify if:
- Must not have taken part in this study previously
- Must not have participated in Amgen study number 20101120.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Amgenlead
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
MD
Amgen
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 5, 2012
First Posted
July 30, 2012
Study Start
March 1, 2012
Primary Completion
November 1, 2014
Study Completion
November 1, 2014
Last Updated
September 9, 2022
Record last verified: 2022-09